A team of researchers led by UC San Francisco scientists has identified a new drug target for triple-negative breast cancer, an aggressive disease subtype that has the poorest outcomes and accounts for as many as one in five cases. 

UC San Francisco is helping to launch a landmark effort by the National Institutes of Health to engage 1 million or more U.S. participants in research aimed at preventing and treating disease based on individual differences in lifestyle, environment and genetics.

Scientists across the University of California system are taking aim at breast cancer. Along with developing better detection methods, researchers are making advances in imaging techniques and tapping into advances in genetics and immunology to develop more refined approaches to treatment.

There’s good news on the breast cancer front: Advances in medicine are helping more women than ever survive a breast cancer diagnosis.

The National Institutes of Health (NIH) has awarded grants to seven UC San Francisco scientists to pursue innovative approaches to major contemporary challenges in biomedical research.